Table 5.
Comparison of the effect of selected mitocan combinations on AML cell lines, primary AML samples, and healthy PBMCs.
| Drug combination | Mean synergy coefficient | ||
|---|---|---|---|
| AML cell linesa | Primary AML samplesb | Normal PBMCsc | |
| IACS/VIN | 34.4 | 31.4 | 4.9 |
| RT/2-DG | 39.9 | 66.1 | −8.0 |
| CCCP/DAS | 30.8 | 21.9 | −19.3 |
| ABT-199/LND | 23.9 | 15.3 | −6.7 |
a
Shown is the mean of maximal synergy between MOLM-13 and OCI-AML2 cell lines.
b
Shown is the mean of maximal synergy between all analyzed primary AML samples (n = 12).
c
Shown is the mean synergy in PBMCs corresponding to the dose resulting in maximal difference in survival AML vs. PBMC (for doses, see Table 2).